Skip to content

Multi-center practical clinical study of Xingqi Xiaoying granule in the treatment of Hashimoto's thyroiditis with qi stagnation and phlegm obstruction

Multi-center practical clinical study of Xingqi Xiaoying granule in the treatment of Hashimoto's thyroiditis with qi stagnation and phlegm obstruction

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300079224
Enrollment
Unknown
Registered
2023-12-27
Start date
2024-01-01
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hashimoto thyroiditis

Interventions

Experimental group:Xingqi Xiaoying granule: (preparation record number: Shanyao preparation word Z20190003000), medication method: 1 bag of boiled water, twice a day
Control group:Selenium yeast tablets (Mudanjiang Lingtai Pharmaceutical Co., LTD. Production, Chinese medicine approval word: H0940161, 50 µg per tablet), once a day, 100 µg each time, oral

Sponsors

Shaanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged between 18-70 years old, regardless of gender; (2) meet the diagnostic criteria of traditional Chinese and western medicine and the dialectical criteria of traditional Chinese medicine with normal serum FT3, FT4 and TSH; (3) those who voluntarily participated in the study, actively cooperated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) patients with thyroid tumors; (2) thyroid surgery or 131I therapy; (3) recent use of antithyroid drugs or thyroid hormone supplementation, or use of immunomodulatory drugs such as selenium preparations or glucocorticoids within 6 months; (4) patients with serious primary diseases such as cardiovascular, cerebrovascular, hepatic, renal and hematological diseases or serious mental or psychological diseases; (5) women who are preparing for pregnancy, pregnant or lactating;

Design outcomes

Primary

MeasureTime frame
TPOAb;TGAb;

Secondary

MeasureTime frame
thyroid function;thyroid ultrasound;

Countries

China

Contacts

Public ContactXiao Yang

Shaanxi Provincial Hospital of Traditional Chinese Medicine

9964170@qq.com+86 153 3922 0808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026